Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inozyme Pharma, Inc. (INZY : NSDQ)
 
 • Company Description   
Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.

Number of Employees: 67

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.33 Daily Weekly Monthly
20 Day Moving Average: 1,030,700 shares
Shares Outstanding: 64.56 (millions)
Market Capitalization: $85.87 (millions)
Beta: 1.35
52 Week High: $6.24
52 Week Low: $0.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 46.81% 42.27%
12 Week -1.48% 5.88%
Year To Date -51.99% -49.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
321 SUMMER STREET SUITE 400
-
BOSTON,MA 02210
USA
ph: 857-330-4340
fax: -
investorrelations@inozyme.com http://www.inozyme.com
 
 • General Corporate Information   
Officers
Douglas A. Treco - Chief Executive Officer and Chairman
Sanjay Subramanian - Chief Financial Officer
Sarah Bhagat - Director
Axel Bolte - Director
Reinaldo Diaz - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45790W108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/06/25
Share - Related Items
Shares Outstanding: 64.56
Most Recent Split Date: (:1)
Beta: 1.35
Market Capitalization: $85.87 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 13.46% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: -7.69%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -
12/31/24 - -115.29
09/30/24 - -88.42
ROA
03/31/25 - -
12/31/24 - -68.09
09/30/24 - -57.02
Current Ratio
03/31/25 - -
12/31/24 - 3.56
09/30/24 - 7.68
Quick Ratio
03/31/25 - -
12/31/24 - 3.56
09/30/24 - 7.68
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - -
12/31/24 - 0.90
09/30/24 - 1.29
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.54
09/30/24 - 0.51
Debt-to-Capital
03/31/25 - -
12/31/24 - 35.23
09/30/24 - 33.69
 

Powered by Zacks Investment Research ©